Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$2.98 +2.6%	$2.01	$1.10 ▼ $3.24	$165.36M	3.03	229,443 shs	86,912 shs
ENTA Enanta Pharmaceuticals	$8.48 +3.8%	$7.41	$4.09 ▼ $13.43	$180.82M	0.88	281,800 shs	186,512 shs
KLTO Klotho Neurosciences	$0.78 -1.1%	$1.21	$0.11 ▼ $3.91	$35.82M	10.9	17.60 million shs	1.06 million shs
THTX Theratechnologies	$3.25 -0.2%	$2.92	$1.12 ▼ $3.25	$149.21M	0.52	1.42 million shs	190,601 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	+1.75%	+9.43%	+59.34%	+88.31%	+39.10%
ENTA Enanta Pharmaceuticals	+2.13%	+25.89%	+8.36%	+34.60%	-33.03%
KLTO Klotho Neurosciences	-8.58%	-5.49%	-39.05%	+261.52%	+78,629,900.00%
THTX Theratechnologies	0.00%	+1.25%	+3.18%	+24.14%	+139.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLLS Cellectis	3.3229 of 5 stars	3.5	5.0	0.0	0.0	3.0	2.5	0.0
ENTA Enanta Pharmaceuticals	3.6258 of 5 stars	3.5	0.0	0.0	4.7	1.9	2.5	0.0
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLLS Cellectis	3.00	Buy	$4.00	34.45% Upside
ENTA Enanta Pharmaceuticals	3.00	Buy	$21.67	155.38% Upside
KLTO Klotho Neurosciences	0.00	N/A	N/A	N/A
THTX Theratechnologies	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest KLTO, CLLS, THTX, and ENTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$24.00 ➝ $25.00
7/28/2025	ENTA Enanta Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
7/3/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLLS Cellectis	$56.30M	2.94	N/A	N/A	$2.36 per share	1.26
ENTA Enanta Pharmaceuticals	$64.81M	2.80	N/A	N/A	$6.08 per share	1.40
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A
THTX Theratechnologies	$84.38M	1.77	N/A	N/A	($0.55) per share	-5.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLLS Cellectis	-$36.76M	-$0.82	N/A	N/A	N/A	-100.69%	-68.05%	-21.53%	11/3/2025 (Estimated)
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.32	N/A	N/A	N/A	-141.98%	-89.02%	-27.28%	N/A
KLTO Klotho Neurosciences	-$6.15M	-$0.45	N/A	∞	N/A	N/A	-1,779.01%	-275.01%	N/A
THTX Theratechnologies	-$8.31M	-$0.19	N/A	46.36	N/A	-10.85%	N/A	-9.83%	10/9/2025 (Estimated)

Latest KLTO, CLLS, THTX, and ENTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	Q2 2025	KLTO Klotho Neurosciences	N/A	-$0.12	N/A	-$0.12	N/A	N/A
8/11/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.25	-$0.85	+$0.40	-$0.85	$16.21 million	$18.31 million
8/4/2025	Q2 2025	CLLS Cellectis	-$0.15	-$0.24	-$0.09	-$0.24	$10.07 million	$18.19 million
7/9/2025	Q2 2025	THTX Theratechnologies	-$0.01	-$0.09	-$0.08	-$0.09	$24.30 million	$17,729.00 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLLS Cellectis	0.58	1.38	1.38
ENTA Enanta Pharmaceuticals	N/A	5.00	5.00
KLTO Klotho Neurosciences	N/A	0.29	0.29
THTX Theratechnologies	N/A	0.84	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLLS Cellectis	63.90%
ENTA Enanta Pharmaceuticals	94.99%
KLTO Klotho Neurosciences	20.07%
THTX Theratechnologies	N/A

Insider Ownership

Company	Insider Ownership
CLLS Cellectis	16.41%
ENTA Enanta Pharmaceuticals	13.89%
KLTO Klotho Neurosciences	26.70%
THTX Theratechnologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
KLTO Klotho Neurosciences	N/A	46.05 million	33.76 million	N/A
THTX Theratechnologies	140	45.98 million	N/A	Optionable

KLTO, CLLS, THTX, and ENTA Headlines

Recent News About These Companies

Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak

August 18 at 7:30 AM | globenewswire.com

Theratechnologies (NASDAQ:THTX) Trading Down 0.3% - Here's What Happened

July 31, 2025 | marketbeat.com

AIGH Capital Management LLC Trims Position in Theratechnologies Inc. (NASDAQ:THTX)

July 22, 2025 | marketbeat.com

Theratechnologies Reports Financial Results for the Second Quarter 2025

July 9, 2025 | globenewswire.com

Theratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?

July 7, 2025 | seekingalpha.com

Future Pak to buy Theratechnologies for $254 million

July 4, 2025 | thepharmaletter.comT

Theratechnologies Stock (NASDAQ:THTX), Insider Trading Activity

July 3, 2025 | benzinga.com

Theratechnologies Inc. (THTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Theratechnologies Stock Short Interest Report | NASDAQ:THTX - Benzinga

July 3, 2025 | benzinga.com

Theratechnologies shareholders should take the deal, Research Capital says

July 3, 2025 | cantechletter.comC

Theratechnologies to be bought by CB Biotechnology for $254M

July 3, 2025 | msn.com

Theratechnologies to Announce Second Quarter 2025 Financial Results

July 3, 2025 | globenewswire.com

Theratechnologies to be Acquired by Future Pak Affiliate

July 2, 2025 | tipranks.com

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

July 2, 2025 | finance.yahoo.com

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

July 2, 2025 | globenewswire.com

Theratechnologies Reports on its Annual Meeting of Shareholders

May 29, 2025 | globenewswire.com

Theratechnologies announces annual shareholder meeting

May 4, 2025 | uk.investing.com

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

May 2, 2025 | globenewswire.com

Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer

April 18, 2025 | seekingalpha.com

Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?

April 18, 2025 | msn.com

Theratechnologies to further evaluate potential sale of the company

April 16, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLTO, CLLS, THTX, and ENTA Company Descriptions

Cellectis NASDAQ:CLLS

$2.98 +0.08 (+2.59%)

As of 03:17 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Enanta Pharmaceuticals NASDAQ:ENTA

$8.48 +0.31 (+3.84%)

As of 03:20 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Klotho Neurosciences NASDAQ:KLTO

$0.78 -0.01 (-1.09%)

As of 02:58 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Theratechnologies NASDAQ:THTX

$3.24 -0.01 (-0.15%)

As of 03:10 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time